A phase 2 trial evaluated the use of BeiGene’s PD-1 inhibitor, Tevimbra, in patients with operable esophageal cancer following standard preoperative chemoradiation. The addition of Tevimbra before surgery led to a higher pathological complete response rate and promising progression-free survival trends, potentially redefining the standard of care for treating operable esophagus tumors.
1. Phase 2 trial evaluated BeiGene’s PD-1 inhibitor, Tevimbra, in operable esophageal cancer. 2. Addition of Tevimbra before surgery led to higher pathological complete response rates. 3. 44 patients in the Tevimbra group achieved a pathological complete response compared with 18.1% in the control group. 4. At 1 year, 95.6% of patients who received Tevimbra remained alive without disease progression. 5. The results may redefine the standard of care for treating operable esophagus tumors.
Listen Tab content
